This company has been marked as potentially delisted and may not be actively trading. resTORbio (TORC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TORC vs. WHWK, SPRB, LITS, AADI, ELYM, ATNM, NBRV, EGRX, PYRGF, and LNAIShould you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Whitehawk Therapeutics (WHWK), Spruce Biosciences (SPRB), Lite Strategy (LITS), Aadi Bioscience (AADI), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Eagle Pharmaceuticals (EGRX), PyroGenesis Canada (PYRGF), and Lunai Bioworks (LNAI). resTORbio vs. Its Competitors Whitehawk Therapeutics Spruce Biosciences Lite Strategy Aadi Bioscience Eliem Therapeutics Actinium Pharmaceuticals Nabriva Therapeutics Eagle Pharmaceuticals PyroGenesis Canada Lunai Bioworks Whitehawk Therapeutics (NASDAQ:WHWK) and resTORbio (NASDAQ:TORC) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment. Does the media prefer WHWK or TORC? In the previous week, Whitehawk Therapeutics had 5 more articles in the media than resTORbio. MarketBeat recorded 5 mentions for Whitehawk Therapeutics and 0 mentions for resTORbio. Whitehawk Therapeutics' average media sentiment score of 1.10 beat resTORbio's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Whitehawk Therapeutics Positive resTORbio Neutral Which has better earnings and valuation, WHWK or TORC? Whitehawk Therapeutics has higher revenue and earnings than resTORbio. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWhitehawk Therapeutics$25.98M3.70-$63.69M-$0.06-34.00resTORbioN/AN/A-$82.74M-$2.41-0.41 Do insiders & institutionals believe in WHWK or TORC? 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 46.2% of resTORbio shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 11.8% of resTORbio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, WHWK or TORC? Whitehawk Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, resTORbio has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Do analysts recommend WHWK or TORC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Whitehawk Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50resTORbio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is WHWK or TORC more profitable? Whitehawk Therapeutics has a net margin of 99.42% compared to resTORbio's net margin of 0.00%. Whitehawk Therapeutics' return on equity of -75.99% beat resTORbio's return on equity.Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics99.42% -75.99% -68.57% resTORbio N/A -78.12%-71.63% SummaryWhitehawk Therapeutics beats resTORbio on 11 of the 13 factors compared between the two stocks. Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TORC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TORC vs. The Competition Export to ExcelMetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.70M$787.62M$6.05B$10.30BDividend YieldN/A4.84%5.73%4.82%P/E Ratio-0.541.2884.9827.10Price / SalesN/A29.85597.99133.24Price / CashN/A17.6425.7730.18Price / Book0.447.5412.516.69Net Income-$82.74M-$7.59M$3.32B$276.55M resTORbio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TORCresTORbioN/A$0.98+1.3%N/A-30.4%$35.70MN/A-0.54N/AGap UpHigh Trading VolumeWHWKWhitehawk Therapeutics1.0009 of 5 stars$2.13-4.1%N/AN/A$100.39M$25.98M-35.5021SPRBSpruce Biosciences0.6525 of 5 stars$160.07-12.3%$131.25-18.0%+377.2%$89.64M$4.91M-1.8620Gap UpHigh Trading VolumeLITSLite StrategyN/A$2.50+2.0%N/AN/A$89.13M$65.30M-0.53100Gap DownAADIAadi BioscienceN/A$2.22+3.3%N/A-1.5%$54.83M$25.07M-0.9740News CoverageELYMEliem TherapeuticsN/A$1.81-8.6%N/A-66.8%$53.85MN/A-3.429ATNMActinium Pharmaceuticals2.1423 of 5 stars$1.54-2.5%$4.50+192.2%-10.6%$48.04MN/A-1.1130News CoverageNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070EGRXEagle Pharmaceuticals1.3691 of 5 stars$3.00flatN/A+71.4%$38.96M$257.55M0.00100Gap DownPYRGFPyroGenesis Canada0.0713 of 5 stars$0.19+3.3%N/A-68.3%$35.50M$9.14M-3.1690Gap DownLNAILunai BioworksN/A$1.24-1.6%N/AN/A$28.74MN/A-0.1620 Related Companies and Tools Related Companies Whitehawk Therapeutics Alternatives Spruce Biosciences Alternatives Lite Strategy Alternatives Aadi Bioscience Alternatives Eliem Therapeutics Alternatives Actinium Pharmaceuticals Alternatives Nabriva Therapeutics Alternatives Eagle Pharmaceuticals Alternatives PyroGenesis Canada Alternatives Lunai Bioworks Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TORC) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share resTORbio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
